Latest Breaking News On - Eric schoen - Page 1 : comparemela.com

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoNew yorkSouth koreaEric schoenCassava sciences incResearch internationalCassava sciencesPremier research internationalBoth phaseMonitoring boardEfficacy outcomesExtension studyFirst quarterNew york cityCassava science

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesRemi barbierEric schoenCassava sciencesExchange commissionCapital advisorsChief financialNew york cityAny warrantsYork cityRedemption priceCall warrants

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

End-of-day, Thursday, May 2, 2024, Will be the Last and Final Day to Trade SAVAW Warrants on NASDAQ.Monday, May 6, 2024, Will be the Last and Final Day to Cash-Exercise SAVAW Warrants.‘Notice of.

New yorkUnited statesEric schoenCassava sciences incCassava sciencesCompany onFinal dayGuaranteed delivery is availableCassava scienceGuaranteed deliveryYork cityNew york cityRedemption priceCurrent reportRisk factorsWarrant agreement

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery.

Remi barbierMichael marsmanLindsayh burnsMichael zamlootChris cookJim kupiecEric schoenRegulatory affairsIntroduction to cassava sciencesCassava sciencesNational institutes of healthDiscovery development programCorporate overview first quarterAnnual reportPrivate securities litigation reform actNational institutes

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials.

United statesPuerto ricoSouth koreaEric schoenRemi barbierCassava sciencesResearch internationalCassava sciences incSafety monitoring boardRecently evaluatedInterim patient safety databaseOral simufilamOn going phaseBoth phaseClinical safety dataSimufilam are expected